MARTIN P REDMON
Broker in Oxford, MA
License number
Massachusetts 9024215
Issued Date
Dec 20, 1997
Expiration Date
Aug 3, 2002
Type
Salesperson
Address
Address
Oxford, MA 01540
Professional information
Norastemizole Polymorphs
US Patent:
6627646, Sep 30, 2003
Filed:
Jul 17, 2001
Appl. No.:
09/907556
Inventors:
Roger P. Bakale - Shrewsbury MA
Chris Senanayake - Shrewsbury MA
Yaping Hong - Princeton NJ
Kostas Saranteas - Peabody MA
Martin P. Redmon - Oxford MA
Stephen A. Wald - Sudbury MA
Chris Senanayake - Shrewsbury MA
Yaping Hong - Princeton NJ
Kostas Saranteas - Peabody MA
Martin P. Redmon - Oxford MA
Stephen A. Wald - Sudbury MA
Assignee:
Sepracor Inc. - Marlborough MA
International Classification:
A61K 31445
US Classification:
514322, 514303, 514313, 546199
Abstract:
Polymorphic crystalline forms of the antihistaminic drug norasternizole are disclosed. Processes for the production of the preferred polymorph are also disclosed.
Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same
US Patent:
8552192, Oct 8, 2013
Filed:
Dec 22, 2010
Appl. No.:
12/975644
Inventors:
David P. Reed - Salem NH, US
Neil R. Barnes - Melrose MA, US
John C. Kane - West Monroe NY, US
Christopher A. Lee - Freeville NY, US
Martin P. Redmon - Oxford MA, US
Neil R. Barnes - Melrose MA, US
John C. Kane - West Monroe NY, US
Christopher A. Lee - Freeville NY, US
Martin P. Redmon - Oxford MA, US
Assignee:
ArQule, Inc. - Woburn MA
International Classification:
C07D 471/06
US Classification:
546 94
Abstract:
The present invention relates to a form 1 and form 2 polymorph of (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione. The present invention also relates to (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione compounds having a chiral purity greater than 99%, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising these (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a composition comprising (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione having a chiral purity greater than 99% or a form 1 and form 2 polymorph of (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione.
Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same
US Patent:
2014003, Jan 30, 2014
Filed:
Sep 25, 2013
Appl. No.:
14/036672
Inventors:
Neil R. Barnes - Melrose MA, US
John C. Kane - West Monroe NY, US
Christopher A. Lee - Freeville NY, US
Martin P. Redmon - Oxford MA, US
John C. Kane - West Monroe NY, US
Christopher A. Lee - Freeville NY, US
Martin P. Redmon - Oxford MA, US
Assignee:
ArQule, Inc. - Woburn MA
International Classification:
C07D 471/06
US Classification:
546 94
Abstract:
The present invention relates to a form 1 and form 2 polymorph of (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione. The present invention also relates to (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione compounds having a chiral purity greater than 99%, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising these (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a composition comprising (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione having a chiral purity greater than 99% or a form 1 and form 2 polymorph of (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione.
Pharmaceutical Compositions Comprising Norastemizole
US Patent:
2002017, Nov 21, 2002
Filed:
Feb 15, 2002
Appl. No.:
10/075616
Inventors:
Martin Redmon - Oxford MA, US
Hal Butler - Marlborough MA, US
Stephen Wald - Sudbury MA, US
Hal Butler - Marlborough MA, US
Stephen Wald - Sudbury MA, US
International Classification:
A61K031/454
US Classification:
514/322000
Abstract:
The present invention relates to chemically stable pharmaceutical formulations of the potent antihistamine, norastemizole. The compositions can include norastemizole, or a pharmaceutically acceptable salt thereof; a diluent; a binder; a disintegrant; and a lubricant or the compositions can include particles of norastemizole, or a pharmaceutically acceptable salt thereof, coated with an inert coating and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating allergic disorders.
Hydroxy Sulfonate Of Quinone Compounds And Their Uses
US Patent:
7790765, Sep 7, 2010
Filed:
Apr 30, 2008
Appl. No.:
12/150914
Inventors:
Judit Bartis - Westford MA, US
Erika Volckova - Concord MA, US
Manish Tandon - Framingham MA, US
Deirdre Lowe - Salem MA, US
Martin P. Redmon - Oxford MA, US
Erika Volckova - Concord MA, US
Manish Tandon - Framingham MA, US
Deirdre Lowe - Salem MA, US
Martin P. Redmon - Oxford MA, US
Assignee:
ArQule, Inc. - Woburn MA
International Classification:
A61K 31/35, C07D 311/92
US Classification:
514454, 424499, 549389
Abstract:
The present invention provides sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro-2H-benzo(h)chromene-6-sulfonate, and its synthesis and uses in the treatment of cancer.